Two new 'Breakthrough' designations for Enhertu in USA

31 August 2023
daiichi_sankyo_large

Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy designations (BTDs) in the USA.

The first is for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, while the second is for the treatment of patients with HER2 positive (IHC 3+) metastatic colorectal cancer who have received two or more prior regimens.

Enhertu, a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by UK pharma major AstraZeneca (LSE: AZN) and Japan’s Daiichi Sankyo (TYO: 4568). AstraZeneca reported first-half 2023 sales for Enhertu of $104 million and alliance revenues of $475 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology